Tofacitinib for treating active ankylosing spondylitis

2.1 Tofacitinib (Xeljanz, Pfizer) is indicated 'for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy'.

2.2 The dosage schedule is available in the summary of product characteristics for tofacitinib.

2.3 The list price of a 56‑tablet pack of 5 mg tofacitinib is £690.03 (excluding VAT; BNF online, accessed June 2022).

2.4 The company has a commercial arrangement. This makes tofacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.